Shelter Pharma Limited appointed Dr. Vinita Shivraj Gadhvi as an Additional Non-Executive Independent Director on July 31, 2026, strengthening its Board composition with a healthcare professional holding a Ph.D. and over 12 years of industry experience. The appointment, made pursuant to Sections 149, 152, and 161(1) of the Companies Act, 2013, carries a fixed tenure of five consecutive years, during which she will not be liable to retire by rotation, pending final shareholder approval at the next Annual General Meeting.

The Board of Directors approved the appointment following a recommendation from the Nomination and Remuneration Committee. Dr. Gadhvi holds office as an Additional Director until the date of the next Annual General Meeting. The company confirmed that she satisfies all statutory criteria for independence under Section 149(6) of the Companies Act, 2013, and is not related to any existing Director or Key Managerial Personnel. Furthermore, she is not debarred from holding office by SEBI or any other authority.

Reconstitution of CSR Committee

Consequent to the change in Board composition, Shelter Pharma reconstituted its Corporate Social Responsibility (CSR) Committee effective July 31, 2026, in compliance with Section 135 of the Companies Act, 2013. Dr. Gadhvi joins the committee as a member, while Mr. Mosinkhan Gafarkhan Pathan continues as Chairman.

What the Numbers Show

The appointment highlights a strategic focus on integrating deep domain expertise into governance structures. Dr. Gadhvi’s background includes an MBA in Total Quality Management and a Ph.D. focused on the Indian Healthcare Startup Ecosystem. Her professional recognition includes innovation grants from SSIP, GUSEC, and i-Hub Gujarat, along with features in government publications such as Women in Startups. This profile suggests an emphasis on quality assurance, regulatory compliance, and strategic business development within the company’s oversight framework.

The Board meeting commenced at 10:45 A.M. and concluded at 11:15 A.M. on July 31, 2026, in Ahmedabad. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Shelter Pharma has secured an international purchase order worth USD12,285 from Genet International for the supply of veterinary feed supplements. Announced on July 27, 2026, the deal marks a step in the company's expansion into global markets, with management stating it will strengthen its export business and contribute to revenue growth. The order was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The transaction involves the supply of four specific veterinary products: Feedmin Bolus, Regulín Bolus, Lactocal Gel, and Buta-B Bolus. The order is classified as being in the normal course of business and does not involve any related party transactions. Management confirmed that neither the promoters nor group companies have any interest in Genet International.

Order Details

The breakdown of the purchase order by product is as follows:

The total consideration for the order stands at USD12,285. Execution timelines are to be mutually agreed upon as per the purchase order schedule. The company noted that this milestone reflects its growing presence in international markets.

What the Numbers Show

The order composition reveals a diversified product mix within the veterinary feed supplement segment. Lactocal Gel commands the highest unit price at USD2.80 per piece, contributing significantly to the total value despite a lower volume compared to the bolus products. The bolus products, priced at USD1.35 and USD1.90, rely on higher volumes (ranging from 1500 to 2500 units) to generate revenue. This mix suggests Shelter Pharma is leveraging both high-volume commodity items and higher-value specialized gels to penetrate the international market through Genet International.